| URL | https://www.fiercepharma.com/manufacturing/hhs-tap |
| Source | Fierce Pharma |
| Date Published | 09/22/2022 |
| Author Name | Joseph Keenan |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Marinus Pharma |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2022 |
| Capital investment ($): | 12.3 |
| City reshored to: | Radnor |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | ganaxolone |
| What domestic positive factors made reshoring more attractive? | Government Incentives, HHS BARDA |